Amphion Innovations plc
London and New York, 9 December 2016 -Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 8 December 2016 it granted options over ordinary shares in the Company (“Options”) to certain of its Directors as follows:
|Richard Mansell-Jones||600,000||2.38 pence||Monthly over a 36 month period|
|Richard Mansell-Jones||563,000||2.38 pence||Monthly over a 12 month period|
|Miroslaw Izienicki||375,000||2.38 pence||Monthly over a 12 month period|
|Paul Kennedy||375,000||2.38 pence||Monthly over a 12 month period|
All Options commence vesting backdated from 1 August 2016.
The strike price is based on the closing price on 8 December 2016, and the Options are exercisable on the date of vesting. Authority for the allotment of ordinary shares under the Share Option Scheme has already been given by the Shareholders in general meeting.
For further information please contact
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Mark Treharne (Corporate Broking)
+44 (0)20 7382 1100
Plumtree Capital Limited (Financial Adviser)
+44 (0)20 7183 2493
+646 568 7502
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.